Literature DB >> 30684247

Risk Factors Associated with Failure to Achieve the Low Density Lipoprotein Cholesterol Therapeutic Target in Patients with Acute Coronary Syndrome: A Longitudinal, Single Centre Investigation.

Mojgan Hajahmadi Pourrafsanjani1, Ebrahim Khayati Shal2, Sina Khezrpour2.   

Abstract

INTRODUCTION: Reducing low-density lipoprotein cholesterol (LDL-C) to target < 100 mg/dL is considered as a critical therapeutic goal after acute coronary syndrome (ACS). AIM: To evaluate the factors associated with reaching or not this LDL-C target after 6 months of statin therapy.
METHODS: Demographic features and other clinically relevant information from a cohort of patients enrolled from April 3, 2016 through March 20, 2017 were analyzed in the current investigation. All included cases had baseline LDL-C levels ≥ 100 mg/dL. LDL-C levels were determined once again after 6-month of statin therapy for each patient.
RESULTS: Two hundred and thirty two participants were included in the final analysis. One third of patients (33.2%) with ACS with initially elevated LDL-C failed to attain LDL-C goal at 6 months. Spearman correlation test showed that the age, diabetes mellitus, lipid lowering therapy and statin daily dose were among the influential factors associated with LDL-C goal achievement. Furthermore, multiple logistic regression analysis revealed that diabetes mellitus and statin treatment before admission were the only independent predictors of achieving LDL-C goal.
CONCLUSIONS: According to our findings, the drug adherence and use of higher intensity as recommended in secondary prevention are needed to increase the achievement of LDL-C treatment targets.

Entities:  

Keywords:  Acute coronary syndrome; Dyslipidemia; Lipid-lowering therapy; Low-density lipoprotein cholesterol; Statins

Mesh:

Substances:

Year:  2019        PMID: 30684247     DOI: 10.1007/s40292-019-00298-5

Source DB:  PubMed          Journal:  High Blood Press Cardiovasc Prev        ISSN: 1120-9879


  30 in total

1.  American Diabetes Association: clinical practice recommendations 2002.

Authors: 
Journal:  Diabetes Care       Date:  2002-01       Impact factor: 19.112

2.  AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology.

Authors:  S C Smith; S N Blair; R O Bonow; L M Brass; M D Cerqueira; K Dracup; V Fuster; A Gotto; S M Grundy; N H Miller; A Jacobs; D Jones; R M Krauss; L Mosca; I Ockene; R C Pasternak; T Pearson; M A Pfeffer; R D Starke; K A Taubert
Journal:  Circulation       Date:  2001-09-25       Impact factor: 29.690

3.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

Review 4.  Low-density lipoprotein cholesterol reduction and cardiovascular disease prevention: the search for superior treatment.

Authors:  Peter H Jones
Journal:  Am J Med       Date:  2004-03-22       Impact factor: 4.965

5.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.

Authors:  Peter S Sever; Björn Dahlöf; Neil R Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal:  Lancet       Date:  2003-04-05       Impact factor: 79.321

6.  Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins.

Authors:  T C Andrews; C M Ballantyne; J A Hsia; J H Kramer
Journal:  Am J Med       Date:  2001-08-15       Impact factor: 4.965

7.  Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.

Authors:  James A de Lemos; Michael A Blazing; Stephen D Wiviott; Eldrin F Lewis; Keith A A Fox; Harvey D White; Jean-Lucien Rouleau; Terje R Pedersen; Laura H Gardner; Robin Mukherjee; Karen E Ramsey; Joanne Palmisano; David W Bilheimer; Marc A Pfeffer; Robert M Califf; Eugene Braunwald
Journal:  JAMA       Date:  2004-08-30       Impact factor: 56.272

Review 8.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

Authors:  Scott M Grundy; James I Cleeman; C Noel Bairey Merz; H Bryan Brewer; Luther T Clark; Donald B Hunninghake; Richard C Pasternak; Sidney C Smith; Neil J Stone
Journal:  Circulation       Date:  2004-07-13       Impact factor: 29.690

9.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes.

Authors:  Christopher P Cannon; Eugene Braunwald; Carolyn H McCabe; Daniel J Rader; Jean L Rouleau; Rene Belder; Steven V Joyal; Karen A Hill; Marc A Pfeffer; Allan M Skene
Journal:  N Engl J Med       Date:  2004-03-08       Impact factor: 91.245

10.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Authors: 
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321

View more
  2 in total

1.  Relationship between Dietary Habits and Control of Lipid Profiles in Patients with Dyslipidemia Using Pravastatin.

Authors:  Seo Young Kang; Tae Hee Jeon; Keun-Sang Yum; Sung Sunwoo; Hyun-Young Shin; Dae Hyun Kim; Kiduk Kim; Jong Lull Yoon; Jae-Kyung Choi; Young Sik Kim
Journal:  Nutrients       Date:  2021-10-25       Impact factor: 5.717

2.  Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets' attainment in subjects with and without type 2 diabetes.

Authors:  Mario Luca Morieri; Valentina Perrone; Chiara Veronesi; Luca Degli Esposti; Margherita Andretta; Mario Plebani; Gian Paolo Fadini; Saula Vigili de Kreutzenberg; Angelo Avogaro
Journal:  Cardiovasc Diabetol       Date:  2021-07-16       Impact factor: 9.951

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.